About Obsidian Therapeutics, Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://obsidiantx.com
Frequently Asked Questions
What is the 52-week range for OBX?
The 52-week high is $49.9699 and the 52-week low is $12.16.
What is the P/E ratio for OBX?
The P/E ratio data is currently unavailable.
What is the dividend yield for OBX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
ROE data is currently unavailable.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Latest OBX News
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
CAMBRIDGE, Mass., October 02, 2026--Obsidian Therapeutics, Inc. ("Obsidian") (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced a poster presentation of updated data in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from the Phase 1 single-center first-in-human (FIH) study and the Phase 1/2 Agni-01 multicenter study of amsoki
Obsidian Therapeutics To Present Updated Data In Patients With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma From Its Phase 1 Study And The Phase 1/2 Agni-01 Multicenter Study Of Amsokigene Autoleucel
Presentations at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, AZ, November 4-8, 2026. The poster presentation will summarize pooled safety data across the FIH study and
Leerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32
Leerink Partners initiates coverage on Obsidian Therapeutics (NASDAQ:OBX) with a Outperform rating and announces Price Target of $32.
Obsidian Therapeutics: A $1.1 Billion Valuation Leaves Little Margin For Error
Obsidian Therapeutics (OBX) hold call: OBX-115 early melanoma data, valuation vs fair value, dilution risk & runway to 2028.
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday
U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-03 | Jagasia Madan | +37,653 | - | - |
| 2026-08-03 | Norkunas Matthew | +37,653 | - | - |
| 2026-08-03 | ROSS ROBERT W. | +37,653 | - | - |
| 2026-08-03 | Hagen Heidi | +37,653 | - | - |
| 2026-08-03 | Fardis Maria | +37,653 | - | - |
| 2026-08-03 | Barrett Peter | +37,653 | - | - |